OptimizeRx Corp

OptimizeRx Corp. is digital health company, engaging in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

OptimizeRx Corp exceeds revenue expectations, eyes growth through strategic deals

OptimizeRx Corp's strong revenue performance and focus on Real-World Data deals position them for growth despite challenges in revenue retention and operating expenses.
The company's strategic initiatives, including share repurchase, capacity utilization, and omnichannel expansion, showcase resilience and potential for market capture.
By leveraging RWD-AI models, focusing on strategic partnerships, and expanding service offerings, OptimizeRx aims to achieve financial and operational goals in 2023.

OptimizeRx Corp reports solid Q1 performance and eyes growth opportunities

OptimizeRx Corp (OPRX) reported solid Q1 performance, meeting revenue expectations and maintaining full-year outlook with a 10% YoY increase expected. The company showcased strengths in strategic partnerships, RWD-AI solutions, and effective use cases for RWE products.
Despite challenges in operating expenses and net revenue retention rate decline, the company is focused on innovation and growth opportunities through M&A, technology investments, and service expansion. By addressing challenges and leveraging opportunities, OptimizeRx Corp aims for sustainable growth and market differentiation.
With a strong emphasis on product execution, customer ROI, and shareholder value enhancement through a share repurchase program, OptimizeRx Corp is positioning itself for continued success in the healthcare technology sector. The company's strategic initiatives and focus on revenue diversification signal a promising outlook for future growth.

OptimizeRx Corp reports Q2 results, focuses on AI growth

OptimizeRx Corp navigated challenges in Q2 2023 with a focus on financial stability, operational efficiency, and strategic growth initiatives.
Despite disappointment with results, the company remains optimistic about the future of digital marketing in healthcare and the potential of AI-driven solutions.
With a strong balance sheet, emphasis on core business areas, and plans for cost management, OptimizeRx is positioned to capitalize on growth opportunities.
The company's commitment to renewals, upsells, and AI-driven engagement underscores a proactive approach to revenue retention and customer satisfaction.

OptimizeRx Corp (OPRX) beats Q3 expectations, eyes robust 2024 growth

OptimizeRx's Q3 performance exceeded expectations, showcasing strong financials and strategic acquisitions driving growth. While competitors face challenges, OptimizeRx is poised for further expansion and revenue increase in 2024 through enhanced platforms and market opportunities.

OptimizeRx Corp exceeds revenue expectations, eyes $100M target in 2024

OptimizeRx Corp delivered exceptional Q4 2023 results, driven by organic messaging strength and the Medicx Health acquisition.
The company's focus on digital solutions and strategic partnerships positions it well for future growth and capturing pharma spend.
While facing macroeconomic challenges, OptimizeRx's progress in Medicx Health integration and DAAP platform growth present promising opportunities.

OptimizeRx Corp reports robust Q1 performance, eyes sustained growth

OptimizeRx Corp's Q1 2024 performance reflects strong revenue growth, improved gross margin, and positive operating cash flow, underpinned by a focus on DAAP and stakeholder engagement.
While facing challenges in profitability and seasonality impact, the company remains optimistic about scaling DAAP, accelerating revenue growth, and enhancing performance in the second half of the year.
With opportunities to drive revenue through cross-selling, expanding infrastructure, and leveraging AI models, OptimizeRx is poised for sustainable growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Will Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial and Operating Officer Steve Silvestro - Chief Commercial Officer Marion Odence-Ford - General Counsel and Chief Compliance Officer Andrew D'Silva - Senior Vice President, Corporate Finance Conference Call Participants Jared Haase - William Blair Sean Dodge - RBC Stephanie Davis - SVB David Grossman - Stifel Neil Chatterji - B. Riley Max Michaels - Lake Street Capital Markets Operator Good afternoon, everyone.

OptimizeRx Corporation (OPRX) Q1 2023 Earnings Call Transcript

OptimizeRx Corp. (OPRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.01 per share a year ago.

OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates

ROCHESTER, Mich., May 10, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended March 31, 2023. Quarterly comparisons are to the same year-ago period.

OptimizeRx Reports First Quarter 2023 Financial Results

ROCHESTER, Mich., April 04, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy has published its 2023 Environmental, Social and Governance (ESG) report.

OptimizeRx Releases 2023 Environmental, Social and Governance (ESG) Report

OptimizeRx Corporation is an interesting company with an investment thesis based on its ability to capture a large TAM, with customers being some of the largest pharma companies out there. The company's financial position is robust and they have been able to grow its top line at a notable and impressive rate recently.

OptimizeRx Has A Good Growth Path Ahead

– AI driven RWD deals grow from 6 completed in 2022 to several dozen in pipeline today, representing the rapid adoption of OptimizeRx's health technology enablement platform services – AI driven RWD deals grow from 6 completed in 2022 to several dozen in pipeline today, representing the rapid adoption of OptimizeRx's health technology enablement platform services

Financial Times Ranks OptimizeRx Amongst The Americas' Fastest Growing Companies for the Fourth Consecutive Year

OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

OptimizeRx Corp. (OPRX) Soars 7.2%: Is Further Upside Left in the Stock?

AdaptHealth Corp

Cara Therapeutics

Infinity Pharma

Alpha Teknova

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

ROCHESTER, Mich., March 14, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that its Board of Directors has unanimously authorized a share repurchase program, under which OptimizeRx may repurchase up to $15 million of its outstanding common stock.

OptimizeRx Authorizes $15 Million Share Repurchase Program

Deal will enable high-growth patient services company to streamline and enhance its services with OptimizeRx's technology solutions Deal will enable high-growth patient services company to streamline and enhance its services with OptimizeRx's technology solutions

OptimizeRx Announces Multi-Year Agreement with Top Hub Services Provider to Accelerate Access for Patients

OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Will Febbo - CEO Ed Stelmakh - CFO and COO Steve Silvestro - Chief Commercial Officer Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Stephanie Davis - SVB David Grossman - Stifel Neil Chatterji - B. Riley Eric Martinuzzi - Lake Street Operator Good afternoon everyone and thank you for joining OptimizeRx's Fourth Quarter Fiscal 2022 Earnings Discussion.

OptimizeRx Corporation (OPRX) Q4 2022 Earnings Call Transcript

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 4.17% and 9.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Q4 Earnings Beat Estimates

ROCHESTER, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2022.

OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results

OptimizeRx (OPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy OptimizeRx (OPRX) Ahead of Earnings?

ROCHESTER, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and fiscal year, ended December 31, 2022. The financial results will be issued in a press release prior to the call.

OptimizeRx Sets Fourth Quarter & Fiscal Year 2022 Conference Call for March 8, 2023 at 4:30 p.m. ET

OptimizeRx Corp. (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptimizeRx Corp. (OPRX) to Report Q4 Results: Wall Street Expects Earnings Growth

ROCHESTER, Mich., Feb. 09, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced its senior vice president of access and adherence, Karina Castagna, has been named to MM+M's 40 Under 40 List for her accomplishments and contributions to the healthcare marketing industry.

OptimizeRx's Karina Castagna Named to MM+M's 40 Under 40 List of the Medical Marketing Industry's Brightest Young Stars

Strength Seen in OptimizeRx Corp. (OPRX): Can Its 10.1% Jump Turn into More Strength?

ROCHESTER, Mich., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy announced OptimizeRx's CEO Will Febbo is invited to speak at the upcoming J.P. Morgan Healthcare Conference. The OPRX conference presentation is scheduled to begin at 8:15 AM PT on January 12, 2023. Ahead of the conference, OPRX is providing the following business update and key industry trends from management's presentation.

OptimizeRx CEO Issues Open Letter to Shareholders Ahead of Presentation at J.P. Morgan Healthcare Conference

OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Will Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial and Operating Officer Steve Silvestro - Chief Commercial Officer Marion Odence-Ford - General Counsel and Chief Compliance Officer Andrew D'Silva - Senior Vice President, Corporate Finance Conference Call Participants Jared Haase - William Blair Sean Dodge - RBC Capital Markets David Grossman - Stifel Joy Zhang - SVB Securities Eric Martinuzzi - Lake Street Capital Markets Marc Wiesenberger - B. Riley Securities Operator Good afternoon, everyone and thank you for joining OptimizeRx's Third Quarter Fiscal 2022 Earnings Discussion.

OptimizeRx Corporation (OPRX) Q3 2022 Earnings Call Transcript

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 75% and 0.47%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Tops Q3 Earnings Estimates

ROCHESTER, Mich., Nov. 08, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended September 30, 2022. Quarterly comparisons are to the same year-ago period.

OptimizeRx Reports Third Quarter 2022 Financial Results

Virtual event takes place December 1, 2022 Virtual event takes place December 1, 2022

OptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired Event

ROCHESTER, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, November 8, 2022, at 4:30 p.m. Eastern time to discuss its results for the third quarter, ended September 30, 2022. The financial results will be issued in a press release prior to the call.

OptimizeRx Sets Third Quarter Fiscal 2022 Conference Call for Tuesday, November 8 at 4:30 p.m. ET

OptimizeRx has lost roughly 83% over the past twelve months despite showing impressive growth and profitability metrics. The market-wide sell-off is providing an opportunity to establish a position in OPRX. The company is expected to report double-digit growth over the next two years and hit around $95M in 2024, which is a ~2.85x forward price-to-sales.

News for OptimizeRx Corp Stock (OPRX)